What Is the Most Accurate AQP4-IgG Test for NMOSD?

If you are being evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD), the preferred blood test for detecting AQP4-IgG antibodies is a cell-based assay (CBA) ^[1].

It is important to understand that no blood test can diagnose or rule out NMOSD on its own. A diagnosis requires a combination of clinical symptoms (like optic neuritis or spinal cord inflammation), Magnetic Resonance Imaging (MRI) results, the blood test result, and the exclusion of other diseases ^[1][2]. However, finding out which specific test your doctor ordered is important. Because NMOSD requires very specific treatments, receiving the most accurate testing method helps prevent both delayed diagnoses and misdiagnoses.

⚠️ Urgent Safety Reminder: If you are experiencing new or worsening vision loss, limb weakness, numbness, severe nausea/vomiting, or breathing difficulty, seek urgent medical care. Do not wait for antibody test results to get emergency treatment. Never stop or change prescribed medications—including steroids, immunosuppressants, or Multiple Sclerosis (MS) drugs—without directly consulting your prescribing neurologist.

Why Cell-Based Assays (CBAs) are the Preferred Test

To test for NMOSD, laboratories look for antibodies—proteins made by your immune system that mistakenly attack your own body. In NMOSD, these antibodies target a water-channel protein in your central nervous system called aquaporin-4 (AQP4).

Different laboratory methods can be used to find these antibodies, but they are not all equally reliable. Medical consensus recommends a validated CBA, ideally performed by an experienced specialist reference laboratory (a facility that specializes in rare or complex testing) ^[1].

The Risks of Less Sensitive Tests

Getting the right test matters because less accurate methods increase your risk of incorrect results.

The Risk of False Negatives

A false negative happens when the test says you do not have the antibodies, but you actually do. False negatives can delay your diagnosis ^[6]. You are more likely to get a false negative if:

• Your doctor used a less sensitive test, like an ELISA ^[4].
• Your blood was drawn after you started taking immunosuppressive treatments, which can lower the detectable amount of antibodies in your blood ^[7][8]. (Note: Do not delay acute attack treatments just to get a “cleaner” blood draw).

The Risk of False Positives

A false positive means the test detects AQP4 antibodies that aren’t actually there. Specificity is a test’s ability to correctly identify people without the disease. In a large comparison of 21 different assays, specificity ranged from 85.8% to 100% ^[1]. Less specific assays (like certain older IFAs) can trigger false positives, which might lead a doctor to incorrectly diagnose you with NMOSD when you actually have a different condition, like Multiple Sclerosis (MS) ^[9].

Because treatments for MS and NMOSD are different—and some MS drugs can be ineffective or even worsen NMOSD—avoiding a false positive is critical ^[2][10].

Interpreting Your Results

Antibody levels are sometimes reported as a titer (a number reflecting the concentration of antibodies). Titers and cutoffs vary significantly between laboratories, so a number that is “high” at one lab might mean something different at another. Furthermore, titer strength does not reliably measure how severe your disease is or if you are about to have a relapse ^[11].

• If you test Positive: A positive AQP4-IgG test from a validated CBA, combined with matching clinical symptoms and MRI findings, strongly supports an NMOSD diagnosis ^[1][2]. An unexpected, borderline, or “low-positive” result may need to be confirmed by a specialist lab ^[1].
• If you test Negative: A single negative test does not completely rule out NMOSD. Antibody levels can fluctuate, and patients who test negative initially sometimes test positive on a later date ^[12].

What If My Test is Negative but Symptoms Match?

If your symptoms and MRI results strongly point to NMOSD but your blood test is negative, your medical team might take these steps:

1. Repeat the test: Especially if you were tested while on immunosuppressants or during a period of low disease activity ^[12].
2. Test for MOG-IgG: MOG-IgG is a different antibody marker. If you test positive for this, it points to a distinct condition called MOG Antibody-Associated Disease (MOGAD), which can mimic NMOSD but requires different management ^[13].
3. Evaluate for Seronegative NMOSD: “Seronegative” means having the disease without detectable AQP4 antibodies. This is a very careful clinical diagnosis that requires stricter clinical and MRI evidence and relies on fully ruling out MS, MOGAD, and other mimicking conditions ^[2].